Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract – A review of patent literature

References

• Rawlings ND, Barrett AJ, Thomas PD, et al. The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database. Nucleic Acids Res. 2018;46(D1):D624–D632.
   PubMed Web of Science ®Google Scholar
• Antalis TM, Bugge TH, Wu Q. Membrane-anchored serine proteases in health and disease. Prog Mol Biol Transl Sci. 2011;99:1–50.
   PubMed Web of Science ®Google Scholar
• Hooper JD, Clements JA, Quigley JP, et al. Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J Biol Chem. 2001;276(2):857–860.
   PubMed Web of Science ®Google Scholar
• Antalis TM, Conway GD, Peroutka RJ, et al. Membrane-anchored proteases in endothelial cell biology. Curr Opin Hematol. 2016;23(3):243–252.
   PubMed Web of Science ®Google Scholar
• Szabo R, Bugge TH. Membrane-anchored serine proteases in vertebrate cell and developmental biology. Annu Rev Cell Dev Biol. 2011;27(1):213–235.
   PubMedGoogle Scholar
• Antalis TM, Buzza MS, Hodge KM, et al. The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment. Biochem J. 2010;428:325–346.
   PubMed Web of Science ®Google Scholar
• Liu M, Hu Z, Qi L, et al. Scanning of novel cancer/testis proteins by human testis proteomic analysis. Proteomics. 2013;13(7):1200–1210.
   PubMed Web of Science ®Google Scholar
• Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008;40(5):569–571.
   PubMed Web of Science ®Google Scholar
• Zoratti GL, Tanabe LM, Hyland TE, et al. Matriptase regulates c-Met mediated proliferation and invasion in inflammatory breast cancer. Oncotarget. 2016;7(36):58162–58173.
   PubMedGoogle Scholar
• Webb SL. Type II transmembrane serine protease (TTSP) deregulation in cancer. Front Biosci. 2011;16(1):539.
   Google Scholar
• Milner JM, Patel A, Davidson RK, et al. Matriptase is a novel initiator of cartilage matrix degradation in osteoarthritis. Arthritis Rheum. 2010;62(7):1955-1966.
   Google Scholar
• Youssefian L, Touati A, Saeidian AH, et al. A novel mutation in ST14 at a functionally significant amino acid residue expands the spectrum of ichthyosis-hypotrichosis syndrome. Orphanet J Rare Dis. 2017;12(1):176.
   PubMedGoogle Scholar
• Désilets A, Béliveau F, Vandal G, et al. Mutation G827R in matriptase causing autosomal recessive ichthyosis with hypotrichosis yields an inactive protease. J Biol Chem. 2008;283(16):10535–10542.
   PubMed Web of Science ®Google Scholar
• Wu Q. The serine protease corin in cardiovascular biology and disease. Front Biosci. 2007;12(8–12):4179–4190.
   PubMedGoogle Scholar
• Peng H, Zhang Q, Shen H, et al. Association between serum soluble corin and obesity in Chinese adults: a cross-sectional study. Obesity (Silver Spring). 2015;23(4):856–861.
   PubMed Web of Science ®Google Scholar
• Folgueras AR, Freitas-Rodríguez S, Ramsay AJ, et al. Matriptase-2 deficiency protects from obesity by modulating iron homeostasis. Nat Commun. 2018;9(1):1350.
   PubMedGoogle Scholar
• Dion SP, Béliveau F, Désilets A, et al. Transcriptome analysis reveals TMPRSS6 isoforms with distinct functionalities. J Cell Mol Med. 2018;22(4):2498–2509.
   PubMed Web of Science ®Google Scholar
• Dion SP, Béliveau F, Morency L-P, et al. Functional diversity of TMPRSS6 isoforms and variants expressed in hepatocellular carcinoma cell lines. Sci Rep. 2018;8(1):12562.
   PubMedGoogle Scholar
• Claborn MK, Stevens DL, Walker CK, et al. Nusinersen: A treatment for spinal muscular atrophy. Ann Pharmacother. 2019;53(1):61–69.
   PubMed Web of Science ®Google Scholar
• Béliveau F. Spécificité enzymatique et régulation fonctionnelle de la matriptase-2, une protéase à sérine transmembranaire de type II essentielle à l’homéostasie du fer: Université de Sherbrooke, Sherbrooke (Qc), Canada, 2012. [Internet]
   Google Scholar
• Consortium G. The Genotype-Tissue Expression (GTEx) project. Nat Genet. 2013;45:580–585.
   PubMed Web of Science ®Google Scholar
• Kim DR, Sharmin S, Inoue M, et al. Cloning and expression of novel mosaic serine proteases with and without a transmembrane domain from human lung. Biochim Biophys Acta - Gene Struct Expr. 2001;1518:204–209.
   PubMedGoogle Scholar
• Donaldson SH, Hirsh A, Li DC, et al. Regulation of the epithelial sodium channel by serine proteases in human airways. J Biol Chem. 2002;277(10):8338–8345.
   PubMed Web of Science ®Google Scholar
• Fasquelle L, Scott HS, Lenoir M, et al. Tmprss3, a transmembrane serine protease deficient in human DFNB8/10 deafness, is critical for cochlear hair cell survival at the onset of hearing. J Biol Chem. 2011;286(19):17383–17397.
   PubMed Web of Science ®Google Scholar
• Beaulieu A, Gravel E, Cloutier A, et al. Matriptase proteolytically activates influenza virus and promotes multicycle replication in the human airway epithelium. J Virol. 2013;87(8):4237–4251.
   PubMed Web of Science ®Google Scholar
• Tsuji A, Torres-Rosado A, Arai T, et al. Hepsin, a cell membrane-associated protease: characterization, tissue distribution, and gene localization. J Biol Chem. 1991;266:16948–16953.
   PubMed Web of Science ®Google Scholar
• Zmora P, Blazejewska P, Moldenhauer A-S, et al. DESC1 and MSPL activate influenza a viruses and emerging coronaviruses for host cell entry. J Virol. 2014;88(20):12087–12097.
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Masuda KI, Ogawa H, et al. Cloning and characterization of the cDNA for human airway trypsin-like protease. J Biol Chem. 1998;273(19):11895–11901.
   PubMed Web of Science ®Google Scholar
• Zmora P, Hoffmann M, Kollmus H, et al. TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1. J Biol Chem. 2018;293(36):13863–13873.
   PubMed Web of Science ®Google Scholar
• Bardou O, Menou A, François C, et al. Membrane-anchored serine protease matriptase is a trigger of pulmonary fibrogenesis. Am J Respir Crit Care Med. 2016;193(8):847–860.
   PubMed Web of Science ®Google Scholar
• Valero-Jiménez A, Zúñiga J, Cisneros J, et al. Transmembrane protease, serine 4 (TMPRSS4) is upregulated in IPF lungs and increases the fibrotic response in bleomycin-induced lung injury. PLoS One. 2018;13(3):e0192963.
   Web of Science ®Google Scholar
• Laporte M, Naesens L. Airway proteases: an emerging drug target for influenza and other respiratory virus infections. Curr Opin Virol. 2017;24:16–24.
   PubMed Web of Science ®Google Scholar
• Böttcher-Friebertshäuser E. Membrane-anchored serine proteases: host cell factors in proteolytic activation of viral glycoproteins. Activation of viruses by host proteases. Springer International Publishing; 2018. p. 153–203.
   Google Scholar
• Murray AS, Varela FA, List K. Type II transmembrane serine proteases as potential targets for cancer therapy. Biol Chem. 2016;397:815–826.
   PubMed Web of Science ®Google Scholar
• Tanabe LM, List K. The role of type II transmembrane serine protease-mediated signaling in cancer. Febs J. 2017;284(10):1421–1436.
   PubMed Web of Science ®Google Scholar
• Bertram S, Dijkman R, Habjan M, et al. TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium. J Virol. 2013;87(11):6150–6160.
   PubMed Web of Science ®Google Scholar
• Gierer S, Bertram S, Kaup F, et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol. 2013;87(10):5502–5511.
   PubMed Web of Science ®Google Scholar
• Glowacka I, Bertram S, Muller MA, et al. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J Virol. 2011;85(9):4122–4134.
   PubMed Web of Science ®Google Scholar
• Shirato K, Kawase M, Matsuyama S. Middle east respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol. 2013;87:12552–12561.
   PubMed Web of Science ®Google Scholar
• Whittaker GR, Millet JK. Biochemical characterization of middle east respiratory syndrome coronavirus spike protein proteolytic processing. Methods Mol Biol. 2020;2099:21–37.
   PubMedGoogle Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2): 271–280.e8.
   PubMed Web of Science ®Google Scholar
• Millet JK, Whittaker GR. Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells. Virology. 2018;517:3–8.
   PubMed Web of Science ®Google Scholar
• Park JE, Li K, Barlan A, et al. Proteolytic processing of middle east respiratory syndrome coronavirus spikes expands virus tropism. Proc Natl Acad Sci U S A. 2016;113(43):12262–12267.
   PubMed Web of Science ®Google Scholar
• White JM, Whittaker GR. Fusion of enveloped viruses in endosomes. Traffic. 2016;17:593–614.
   PubMed Web of Science ®Google Scholar
• Shin W-J, Seong BL. Type II transmembrane serine proteases as potential target for anti-influenza drug discovery. Expert Opin Drug Discov. 2017;12(11):1139–1152.
   PubMed Web of Science ®Google Scholar
• Bottcher-Friebertshauser E, Stein DA, Klenk H-D, et al. Inhibition of influenza virus infection in human airway cell cultures by an antisense peptide-conjugated morpholino oligomer targeting the hemagglutinin-activating protease TMPRSS2. J Virol. 2011;85(4):1554–1562.
   PubMed Web of Science ®Google Scholar
• Böttcher-Friebertshäuser E, Lu Y, Meyer D, et al. Hemagglutinin activating host cell proteases provide promising drug targets for the treatment of influenza A and B virus infections. Vaccine. 2012;30(51):7374–7380.
   PubMed Web of Science ®Google Scholar
• Meyer D, Sielaff F, Hammami M, et al. Identification of the first synthetic inhibitors of the type II transmembrane serine protease TMPRSS2 suitable for inhibition of influenza virus activation. Biochem J. 2013;452(2): 331–343.
   PubMed Web of Science ®Google Scholar
• Sielaff F, Böttcher-Friebertshäuser E, Meyer D, et al. Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT. Bioorganic Med Chem Lett. 2011;21(16):4860–4864.
   PubMed Web of Science ®Google Scholar
• Nygaard RM, Golden JW, Schiff LA. Impact of host proteases on reovirus infection in the respiratory tract. J Virol. 2012;86(2):1238–1243.
   PubMed Web of Science ®Google Scholar
• Menou A, Duitman J, Flajolet P, et al. Human airway trypsin-like protease, a serine protease involved in respiratory diseases. Am J Lung Cell Mol Physiol. 2017;312(5):657–668.
   Web of Science ®Google Scholar
• Jung H, Lee KP, Park SJ, et al. TMPRSS4 promotes invasion, migration and metastasis of human tumor cells by facilitating an epithelial–mesenchymal transition. Oncogene. 2008;27(18):2635–2647.
   PubMed Web of Science ®Google Scholar
• Exposito F, Villalba M, Redrado M, et al. Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery. Cancer Lett. 2019;453:21–33.
   PubMed Web of Science ®Google Scholar
• Larzabal L, Nguewa PA, Pio R, et al. Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology. Br J Cancer. 2011;105(10):1608–1614.
   PubMed Web of Science ®Google Scholar
• Iwakiri K, Ghazizadeh M, Jin E, et al. Human airway trypsin-like protease induces PAR-2-mediated IL-8 release in psoriasis vulgaris. J Invest Dermatol. 2004;122(4):937–944.
   PubMed Web of Science ®Google Scholar
• Chen C-J, Wu B-Y, Tsao P-I, et al. Increased matriptase zymogen activation in inflammatory skin disorders. Am J Physiol Physiol. 2011;300(3):C406–C415.
   PubMed Web of Science ®Google Scholar
• Wilkinson DJ, Desilets A, Lin H, et al. The serine proteinase hepsin is an activator of pro-matrix metalloproteinases: molecular mechanisms and implications for extracellular matrix turnover. Sci Rep. 2017;7(1):16693.
   PubMedGoogle Scholar
• Wilkinson DJ, Habgood A, Lamb HK, et al. Matriptase induction of metalloproteinase-dependent aggrecanolysis in vitro and in vivo: promotion of osteoarthritic cartilage damage by multiple mechanisms. Arthritis Rheumatol. 2017;69(8):1601–1611.
   PubMed Web of Science ®Google Scholar
• Rather GM, Lin S-Y, Lin H, et al. Activated matriptase as a target to treat breast cancer with a drug conjugate. Oncotarget. 2018;9(40):25983–25992.
   PubMedGoogle Scholar
• Zoratti GL, Tanabe LM, Varela FA, et al. Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling. Nat Commun. 2015;6(1):6776.
   PubMedGoogle Scholar
• Xing P, Li JG, Jin F, et al. Clinical and biological significance of hepsin overexpression in breast cancer. J Investig Med. 2011;59(5):803–810.
   PubMed Web of Science ®Google Scholar
• Wu S-R, Cheng T-S, Chen W-C, et al. Matriptase is involved in ErbB-2-induced prostate cancer cell invasion. Am J Pathol. 2010;177(6):3145–3158.
   PubMed Web of Science ®Google Scholar
• Förbs D, Thiel S, Stella MC, et al. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol. 2005;27:1061–1070.
   PubMed Web of Science ®Google Scholar
• Magee JA, Araki T, Patil S, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res. 2001;61:5692–5696.
   PubMed Web of Science ®Google Scholar
• Wu Q, Parry G. Hepsin and prostate cancer. Front. Biosci. Front Biosci. 2007;12(12):5052–5059.
   PubMedGoogle Scholar
• Damalanka VC, Han Z, Karmakar P, et al. Discovery of selective matriptase and hepsin serine protease inhibitors: useful chemical tools for cancer cell biology. J Med Chem. 2019;62(2):480–490.
   PubMed Web of Science ®Google Scholar
• Koschubs T, Dengl S, Dürr H, et al. Allosteric antibody inhibition of human hepsin protease. Biochem J. 2012;442(3):483–494.
   PubMedGoogle Scholar
• Wang Z, Wang Y, Zhang J, et al. Significance of the TMPRSS2: ERG gene fusion in prostate cancer. Mol Med Rep. 2017;16(4):5450–5458.
   PubMed Web of Science ®Google Scholar
• Lucas JM, Heinlein C, Kim T, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 2014;4(11):1310–1325.
   PubMed Web of Science ®Google Scholar
• Obinata D, Ito A, Fujiwara K, et al. Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth. Cancer Sci. 2014;105(10):1272–1278.
   PubMed Web of Science ®Google Scholar
• Wambier CG, Goren A. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. J Am Acad Dermatol. 2020;83(1):308–309.
   Web of Science ®Google Scholar
• Azouz NP, Klingler AM, Rothenberg ME. Alpha 1 antitrypsin is an inhibitor of the SARS-CoV2–priming protease TMPRSS2. bioRxiv. 2020 May 04:077826; doi: https://doi.org/10.1101/2020.05.04.077826.
   Google Scholar
• Luke Danahay H, Mark LeGrand D, Tully DC, et al. Organic compounds. US20120208882. 2012.
   Google Scholar
• Kawase M, Shirato K, van der Hoek L, et al. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J Virol. 2012;86(12):6537–6545.
   PubMed Web of Science ®Google Scholar
• Asakura H, Ogawa H. Potential of heparin and nafamostat combination therapy for COVID‐19. J Thromb Haemost. 2020;18(6):1521-1522.
   PubMed Web of Science ®Google Scholar
• Jang S, Rhee J-Y. Three cases of treatment with Nafamostat in elderly patients with COVID-19 pneumonia who need oxygen therapy. Int J Infect Dis. 2020;96:500–502.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Schroeder S, Kleine-Weber H, et al. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother. 2020;64(6):19–21.
   Web of Science ®Google Scholar
• AOYAMA T, INO Y, OZEKI M, et al. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol. 1984;35(3):203–227.
   PubMedGoogle Scholar
• Steinmetzer T, Meyer D, Hammami M, et al. Use of tmprss2 inhibitors as medicaments. WO2013014074. 2013.
   Google Scholar
• Steinmetzer T, Schweinitz A, Donnecke D Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors. US8569313. 2013.
   Google Scholar
• Steinmetzer T, Sielaff F, Garten W, et al. Use of hat inhibitors and tmprss2 inhibitors as medicaments. EP2435064 . 2010. [Internet]
   Google Scholar
• Tully DC, Chatterjee AK, Vidal A, et al. Compounds and compositions as channel activating protease inhibitors. US8338469 . 2012. [Internet]
   Google Scholar
• Richter M, Leduc R, Colombo E, et al. Matriptase inhibitors and uses thereof against orthomyxoviridae infections. US10208308 . 2019. [Internet]
   Google Scholar
• Colombo E, Désilets A, Duchêne D, et al. Design and synthesis of potent, selective inhibitors of matriptase. ACS Med Chem Lett. 2012;3(7):530–534.
   PubMed Web of Science ®Google Scholar
• St-Georges C, Désilets A, Béliveau F, et al. Modulating the selectivity of matriptase-2 inhibitors with unnatural amino acids. Eur J Med Chem. 2017;129:110–123.
   PubMed Web of Science ®Google Scholar
• Duchêne D, Colombo E, Désilets A, et al. Analysis of subpocket selectivity and identification of potent selective inhibitors for matriptase and matriptase-2. J Med Chem. 2014;57(23):10198–10204.
   PubMed Web of Science ®Google Scholar
• Boudreault P-L, Colombo É, Leduc R, et al. Matriptase inhibitors and uses thereof. US20190337981 . 2019. [Internet]
   Google Scholar
• Janetka JW, Han Z, Harris P, et al. Inhibitors of growth factor activation enzymes. US20180066015 . 2018. [Internet]
   Google Scholar
• List K. Matriptase: A culprit in cancer? Futur. Oncol. Future Oncol. 2009;5(1):97–104.
   PubMed Web of Science ®Google Scholar
• Tseng I-C, Xu H, Chou F-P, et al. Matriptase activation, an early cellular response to acidosis. J Biol Chem. 2010;285(5):3261–3270.
   PubMed Web of Science ®Google Scholar
• Lin C-Y, Dickson RB, Wang S, et al. Structure based discovery of inhibitors of matriptase for the treatment of cancer and other conditions. US6677377 [Internet]. 2004.
   Google Scholar
• Duncan DF, Alfaro-Lopez LJ, Komandla M, et al. Matriptase inhibitors and methods of use. US7019019 . 2006. [Internet]
   Google Scholar
• Joossens J, Augustyns K, Lambeir A-M, et al. KLK4 inhibitors. US10017527 . 2018. [Internet]
   Google Scholar
• Obiezu CV, Diamandis EP. Human tissue kallikrein gene family: applications in cancer. Cancer Lett. Elsevier. 2005;224(1):1–22.
   PubMed Web of Science ®Google Scholar
• Walker B, Martin L, Ferguson T. Binding Compound and Uses Thereof. US20200010505 . 2020. [Internet]
   Google Scholar
• Luckett S, Garcia RS, Barker JJ, et al. High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds. J Mol Biol. 1999;290(2):525–533.
   PubMed Web of Science ®Google Scholar
• Kennedy AR. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr. 1998;68(6):1406S-1412S. American Society for Nutrition.
   PubMed Web of Science ®Google Scholar
• Korsinczky M, Schirra H, Craik D. Sunflower Trypsin Inhibitor-1. Curr Protein Pept Sci. 2005;5(5):351–364.
   Web of Science ®Google Scholar
• Long YQ, Lee SL, Lin CY, et al. Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase. Bioorganic Med Chem Lett. 2001;11(18):2515–2519.
   PubMed Web of Science ®Google Scholar
• Roller PP, Li P Serine protease inhibitors. US7439226 . 2008. [Internet]
   Google Scholar
• Harris JM, Swedberg JE Novel protease inhibitors. WO2010017587 . 2010. [Internet]
   Google Scholar
• Harris JM, De Veer SJ, Swedberg JE Serine protease inhibitors. WO2012083385 . 2012. [Internet]
   Google Scholar
• Galemmo RA, Bansal N, Klampfer L, et al. Inhibitors of hepatocyte growth factor [hgf] and macrophage stimulating protein [msp] maturation. WO2015184222 . 2015. [Internet]
   Google Scholar
• Venukadasula PKM, Owusu BY, Bansal N, et al. Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation. ACS Med Chem Lett. 2016;7(2):177–181.
   PubMed Web of Science ®Google Scholar
• Youngjoo B Hepsin inhibitors and pharmaceutical composition for prevention and treatment of the metastasis of prostate cancer. KR1020170045574 . 2017. [Internet]
   Google Scholar
• Kwon H, Kim YH, Park K, et al. Structure-based design, synthesis, and biological evaluation of Leu-Arg dipeptide analogs as novel hepsin inhibitors. Bioorganic Med Chem Lett. 2016;26(2):310–314.
   PubMed Web of Science ®Google Scholar
• Vasioukhin VI, Chevillet JR Hepsin inhibitors. US9182402 . 2015. [Internet]
   Google Scholar
• Chevillet JR, Park GJ, Bedalov A, et al. Identification and characterization of small-molecule inhibitors of hepsin. Mol Cancer Ther. 2008;7(10):3343–3351.
   PubMed Web of Science ®Google Scholar
• Rowan AD, Cawston TE, Milner JM, et al. Screening methods. WO2011023958 . 2011. [Internet]
   Google Scholar
• Yuan C, Chen L, Meehan EJ, et al. Structure of catalytic domain of Matriptase in complex with Sunflower trypsin inhibitor-1. BMC Struct Biol. 2011;11(1):30.
   PubMedGoogle Scholar
• Béliveau F, Tarkar A, Dion SP, et al. Discovery and development of TMPRSS6 inhibitors modulating hepcidin levels in human hepatocytes. Cell Chem Biol. 2019.
   PubMed Web of Science ®Google Scholar
• Goswami R, Mukherjee S, Ghadiyaram C, et al. Structure-guided discovery of 1,3,5 tri-substituted benzenes as potent and selective matriptase inhibitors exhibiting in vivo antitumor efficacy. Bioorg Med Chem. 2014;22(12):3187–3203.
   PubMed Web of Science ®Google Scholar
• Steinmetzer T, Schweinitz A, Stürzebecher A, et al. Secondary Amides of Sulfonylated 3-Amidinophenylalanine. New Potent and Selective Inhibitors of Matriptase †. J Med Chem. 2006;49(14):4116–4126.
   PubMed Web of Science ®Google Scholar
• Park YW, Kim S, Jo K, et al. Anticancer drug comprising inhibitor of TMPRSS4. US8778901 . 2014. [Internet]
   Google Scholar
• Kang S, Min HJ, Kang MS, et al. Discovery of novel 2-hydroxydiarylamide derivatives as TMPRSS4 inhibitors. Bioorganic Med Chem Lett. 2013;23(6):1748–1751.
   PubMed Web of Science ®Google Scholar
• Kim S, Ko D, Lee Y, et al. Anti-cancer activity of the novel 2-hydroxydiarylamide derivatives IMD-0354 and KRT1853 through suppression of cancer cell invasion, proliferation, and survival mediated by TMPRSS4. Sci Rep. 2019;9(1):10003.
   Web of Science ®Google Scholar
• Benam KH 2-naphthimidamides, analogues thereof, and methods of treatment using same. WO2019241213 . 2019. [Internet]
   Google Scholar
• Search of: Camostat | SARS-CoV-2 - List Results. ClinicalTrials.gov [Internet].
   Google Scholar
• Search of: Nafamostat | SARS-CoV-2 - List Results. ClinicalTrials.gov [Internet].
   Google Scholar
• Menou A, Duitman JW, Crestani B. The impaired proteases and anti-proteases balance in Idiopathic Pulmonary Fibrosis. Matrix Biol. 2018;68–69:382–403.
   PubMed Web of Science ®Google Scholar
• Sisson TH, Spagnolo P. Matriptase, protease-activated receptor 2, and idiopathic pulmonary fibrosis: further evidence for signaling pathway redundancy in this difficult-to-treat disease? Am J Respir Crit Care Med. 2016;193(8):816–817. American Thoracic Society.
   PubMed Web of Science ®Google Scholar
• Owusu BY, Thomas S, Venukadasula P, et al. Targeting the tumor-promoting microenvironment in METamplified NSCLC cells with a novel inhibitor of pro-HGF activation. Oncotarget. 2017;8(38):63014–63025.
   PubMedGoogle Scholar